M1 Kliniken AG reports a **23.8% increase in Beauty segment EBIT to EUR 18.6 million** for the first half of 2026, alongside an **11% revenue rise to EUR 56.9 million**. The company completes its strategic refocusing in this core business while selling its 85%-owned subsidiary, **HAEMATO Pharm GmbH**, to the PHOENIX group. The report highlights improved operating performance in its Beauty segment.
M1 Kliniken AG completes the sale of its HAEMATO Pharm GmbH subsidiary, divesting its 85% stake to the PHOENIX group by January 31, 2026. The transaction refocuses the company’s portfolio exclusively on high-margin aesthetic medicine. First-quarter financial results reflect this strategic shift, limiting comparability with prior-year figures.
Hogan Lovells advises **HAEMATO AG** in selling its subsidiary **HAEMATO Pharm GmbH** to the **PHOENIX group**. The deal requires standard antitrust clearance, and both parties have kept financial details confidential. The transaction involves a corporate restructuring within the pharmaceutical sector.
PHOENIX Pharmahandel SE acquires full control of HAEMATO Pharm GmbH from HAEMATO AG. The European Commission approved the transaction in December 2025, following initial agreement in October 2025. Legal advisors Hogan Lovells International LLP supported the deal.
HAEMATO AG is evaluating an offer to sell its trading segment. The company has not yet confirmed whether the deal will proceed or disclosed further details about the transaction. This move could reshape HAEMATO’s operational focus and asset portfolio.
HAEMATO AG acquires **M1 Aesthetics GmbH** from **M1 Kliniken AG** as part of a capital increase in kind. The transaction expands HAEMATO’s portfolio in aesthetic medicine services. The deal aligns with HAEMATO’s growth strategy in specialized healthcare sectors.
M1 Aesthetics
M1 Aesthetics AG, formerly HAEMATO AG, sold pharmaceutical wholesaler HAEMATO Pharm GmbH to PHOENIX group in 2026 and exited trading.